公司簡介

江陰司特易生物技術公司由數名海歸博士創立于2007年12月，主要從事干細胞及生物3D打印技術相關產品的研發和應用，同時根據公司的技術特長，為國內外生物醫藥企業,科研機構和醫院提供干細胞和生物3D打印方面的技術服務。

       2008年,司特易公司成為無錫“530”計劃扶持的企業，在資金和政策方面受到無錫市政府和江陰經濟開發區的大力支持。公司努力吸引管理和技術人才，組建了一個高效的管理團隊和技術團隊。公司團隊充分利用百橋生物園提供的包括中心實驗室在內的軟、硬件服務，努力研發有自主知識產權的干細胞和生物3D打印相關產品，在十年的時間內獲得了豐碩的成果。2009年年初，司特易公司申請到江蘇省科技型企業技術創新資金項目，項目編號為SBC200910486。2011年公司與復旦大學共同申請并榮獲國家“十二五”重大新藥創制項目資助，課題名稱“基因重組人源溶菌酶H-LYZ和 LYC4抗耐藥性病原菌感染的臨床前研究”，課題立項編號2011ZX09102 -007-01。 2008年以來公司與中國科學院魏于全院士進行全面科研合作，共同培養公司在職研究生，在國際、國內干細胞及生物3D打印專業雜志上發表科研論文多篇；并于2014年在江陰組建了院士工作站和干細胞工程研究中心。 2015年與美國生物3D打印公司Allevi（曾用名 BioBots）建立戰略合作關系，全面引進生物3D打印技術軟、硬件。 同年，公司與江南大學申請并獲準成為江蘇省研究生培養基地。2016年，公司聯手南京大學，南京師范大學，南京航空大學和中國科學院蘇州醫工所申請并獲得江蘇省重點科研項目(編號SB2016010)“面向精準醫療的人工髖關節生物三維打印關鍵技術與成套裝備研發”。2016年，公司成功轉讓“治療老年黃斑變性（AMD）多肽”項目給北京一上市公司，為江蘇省重點項目贏得了足夠的配套資金。    

      經過數年的努力，司特易公司的技術團隊全面掌握了包括干細胞的提取，培養，分化，凍存和復蘇在內的干細胞相關技術，同時展開了干細胞相關系列產品的研發；我們根據市場需求，研發、生產出了包括EHS水凝膠、ECM包被耗材、LAP藍光引發劑和FPM滋養蛋白復合物等拳頭產品在內的七類30多個產品。在生物3D打印方面， 公司開發出了包括LAP藍光引發劑，GelMA, HAMA, CSMA, ALMA，ElaMA和ChiMA-LA在內的多種3D打印生物材料（生物墨水）。2012年5月，獲得《細胞配對融合芯片》發明專利； 2015年獲《頸椎牽引枕》專利證書；2017年8月，遞交了4個有關《生物3D打印槍》的專利申請；2018年2月遞交《滋養細胞蛋白復合物(FPM)的制備工藝》的專利申請。

司特易公司的服務外包團隊承接了來自跨國制藥巨頭葛蘭素史克(GSK),中國醫學科學院，清華大學，北京大學，浙江大學，上海交大，四川大學等國內外知名企業和科研院所的外包服務和合作研發項目。通過生物醫藥的外包服務和合作研發，訓練了技術人員，培養了團隊精神，這對公司的可持續發展起到了很大的推動作用。

 展望未來，任重道遠。我們將專注于干細胞和生物3D打印材料（生物墨水）的研發和生產，堅持以人為本、制度為綱、創新為源、產品為先，尋求穩步健康發展。

“路漫漫其修遠兮，吾將上下而求索”__屈原。

陳慧敏 MD, PhD    

司特易生物 CEO    

2018-07-18    

StemEasy Introduction

Jiangyin StemEasy Biotechnology Company (StemEasy, SE) has been founded by several returnees from US in December 2007, mainly engaged in stem cell and 3D bioprinting technology related product development and application.  Based on the company's expertise, we provide technical service on stem cell and 3D bioprinting for domestic and foreign enterprises, institutes and hospitals. 

In 2008, StemEasy became a listed company in "Wuxi “530” Talent Plan, which is a plan to support Western educated returnees going back China to start up enterprises.  In early 2009, StemEasy was granted an Innovation Fund from Science and Technology Agency in Jiangsu Province, the project number is SBC200910486.  In 2011, jointly with Fudan University, we applied for and was awarded State "the 12 Five-year Plan" Major New Drug Project Fund, the project name is "Recombinant Human lysozyme H-LYZ and LYC4 Preclinical Studies on Anti-drug-resistant Bacteria Infection" and the project number is 2011ZX09102-007-01.  Since 2008, our company and Dr. Wei Yuquan, academician of the Chinese Academy of Sciences started our collaboration on scientific research and on-the-job graduate training，co-published a few research papers on stem cell R&D in both domestic and international journals.  In 2014, with Dr. Wei’s and Governments support, StemEasy set up the Jiangyin Academician Workstation and Stem Cell Engineering Research Center.  In March 2015, we established a cooperation with BioBots, a 3D bio-printing company in US, and introduced their 3D Bio-printing technology and hardware into Chinese market.  In 2015, StemEasy become a postgraduate training base of Biotechnology in Jiangsu province.  In 2016, the company teamed up with top 3 universities at Nanjing and Suzhou Medical Engineering Research Institute of Chinese Academy of Sciences, to apply for and obtain the funding from Jiangsu Key Technology RD Program（BE2016010）, entitled "Development of key technologies and complete sets of equipment for 3D printing of Hip Prosthesis System toward precision medicine".

After 8 years’ efforts, the StemEasy's technical team masters many technologies related stem cell extraction, amplification, differentiation, cryopreservation and resuscitation.  Responding the market demands, we developed a series of products for stem cell research, over 30 products, including EHS Hydrogel, Special-coated cell culture plates and Feeder Protein Mix for hESCs expansion and differentiation.  For 3D Bio-printing, the company developed and manufactured LAP (blue light initiator), and a variety of 3D bio-printing materials (Bio ink), e.g. GelMA, HAMA, CSMA and ALMA.  Meanwhile, to protect our IP, we apply patents timely.  In September 2012, we had our first innovation patent in hand, entitled "Paired Cell Fusion Chip".  In 2015, we obtained the patent certificate of "Cervical Traction Pillow"; In August 2017, four patent applications for "the 3D Bioprinting Gun" were submitted. In February 2018, the patent application for "the Preparation Process of Feeder Protein Mix (FPM) " was submitted. 

StemEasy also provides technical services for multinational pharmaceutical companies, e.g. GSK R&D Center in China, Novartis R&D Center, Qinhua University, Beijing University, Zhejiang University, Sichuan University, and the Tianjin International Biomedical Joint Academy.  Through outsourcing and collaboration, we accumulate R&D experiences and buildup our own expertise, which significantly promotes our company’s sustainable progress. 

Looking to the future, we will insist our R&D mission on stem cell and 3D bioprinting material in China, adhere to people foremost, manage company by rules, innovation as the source, product first, and expand our business actively in a steady and healthy pace.  

"The road is long, we’ll persist to look for ultimate truth." __ by Qu Yuan, a Chinese poet.

Harry Huimin Chen, M.D., Ph.D     

        StemEasy Bio, CEO

 July 17, 2018